Aumolertinib With Chemotherapy or Alone Compared With Osimertinib in Patients With Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer
- Conditions
- NSCLC
- Interventions
- Registration Number
- NCT05493501
- Lead Sponsor
- EQRx International, Inc.
- Brief Summary
Aumolertinib is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that targets EGFR mutations. The reason for this study is to learn whether adding chemotherapy to a new investigational drug called aumolertinib helps to slow or stop cancer growth in people with EGFR mutation-positive, locally advanced or metastatic non-small cell lung cancer (NSCLC). The study will compare this new combination of drugs to osimertinib, given alone. Aumolertinib given alone will also be used in the study, and it will be looked at in comparison with osimertinib given alone.
This is a randomized, open-label study with 3 different groups that are listed below. "Randomized" means the study treatment participants take will be chosen by chance (decided at random by a computer). "Open-label" means that the participant, the study doctor, and the Sponsor will know which study treatment each participant is receiving.
Participants will be randomly assigned to one of the following 3 treatment groups:
* Group 1: Treatment with aumolertinib alone, taken orally (by mouth) as a pill once a day. Around 100 participants will be randomly assigned to this group.
* Group 2: Treatment with aumolertinib taken orally as a pill once a day, in combination with chemotherapy given intravenously (IV; through a needle placed in a vein) on the schedule provided by the study doctor. Around 200 participants will be randomly assigned to this group.
* Group 3: Treatment with osimertinib alone, taken orally as a pill once a day. Around 200 participants will be randomly assigned to this group.
Because there will be twice as many participants in Group 2 and Group 3 as in Group 1, the chance of a participant being randomly assigned to either of those groups is twice as likely as being assigned to Group 1.
Participants can continue to receive study treatment as long as they have not withdrawn consent, as long as they choose to continue to receive study treatment and are judged by their doctor to continue to receive clinical benefit from receiving the study treatment, and as long as no other study treatment and/or study discontinuation criteria are met .
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- All
- Target Recruitment
- 8
- Is at least 18 years of age (or the legal age of consent in the jurisdiction in which the study is taking place)
- Has pathologically confirmed NSCLC that is Stage IIIB, metastatic (Stage IVA or IVB), or recurrent, and which is not amenable to curative intent therapy.
- Tumor harbors one of the 2 common EGFR mutations known to be associated with EGFR-TKI sensitivity-ex19del or L858R-either alone or in combination with other EGFR mutations (eg, G719X, exon 20 insertions, S7681, L861Q)
- Has Eastern Cooperative Oncology group performance status of 0, 1, or 2 at the time of enrollment.
- Has adequate organ function at the time of enrollment.
- Has QTc interval of ≤ 470 ms
- Male participants must agree to use a highly effective method of contraception and to refrain from donating sperm while receiving study treatment
- Female participants are eligible to participate if not pregnant or breastfeeding, and at least one of the following conditions applies: is not of childbearing potential OR is of childbearing potential and using a highly effective contraceptive method while receiving study treatment AND agrees not to donate eggs (ova, oocytes) during this period
- All female participants must have a negative serum or urine pregnancy test result within 48 hours prior to initiation of study drug dosing
- Is a candidate for curative intent therapy for the NSCLC diagnosis.
- Tumor has mixed small-cell and non-small-cell pathology.
- Has received prior systemic treatment for metastatic NSCLC. Prior chemotherapy or immunotherapy is permitted, provided that it was used for treatment of locoregional NSCLC as a component of curative intent therapy and administration was completed more than 6 months ago.
- Has refractory nausea and vomiting, chronic gastrointestinal disease(s), inability to swallow the formulated product (percutaneous endoscopic gastrostomy tube administration may be allowed if tablets are not crushed), or a history of previous significant bowel resection-any of which would preclude adequate absorption of aumolertinib or osimertinib.
- Has active or past medical history of interstitial lung disease, drug-induced interstitial lung disease or radiation pneumonitis that required steroid treatment
- Has evidence of active bacterial, viral, or fungal infection which would preclude safe enrollment, as assessed by the treating Investigator.
- Has significant concomitant condition, that in the Investigator's judgment would prevent the participant from receiving study treatment or being followed in this study, or which otherwise renders the participant inappropriate for the study.
- For participants in the aumolertinib monotherapy and aumolertinib with chemotherapy arms, use of strong CYP3A4 inhibitors/inducers within 14 days before initial study drug dosing and use of grapefruit-containing products within 72 hours before initial study drug dosing is prohibited.
- Has a history of prolonged QT syndrome or Torsades de Pointes
- Has any clinically important abnormalities in rhythm, conduction, or morphology of resting ECG, including evidence of QT prolongation (QTc >470 ms for males and >480 ms for females) or has any factor, including any current medication(s), known to increase the risk of QTc prolongation or the risk of arrhythmic events
- Hypersensitivity or allergy to aumolertinib or osimertinib or their excipients
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Aumolertinib monotherapy Aumolertinib monotherapy - Aumolertinib + platinum-based doublet chemotherapy Aumolertinib monotherapy For adenocarcinoma, either: * Aumolertinib + cisplatin with pemetrexed, or * Aumolertinib + carboplatin with pemetrexed For squamous cell carcinoma, one of the following: * Aumolertinib + cisplatin or carboplatin with paclitaxel; * Aumolertinib + cisplatin or carboplatin with albumin-bound paclitaxel; or * Aumolertinib + cisplatin or carboplatin with gemcitabine Osimertinib monotherapy Osimertinib monotherapy - Aumolertinib + platinum-based doublet chemotherapy Nab paclitaxel For adenocarcinoma, either: * Aumolertinib + cisplatin with pemetrexed, or * Aumolertinib + carboplatin with pemetrexed For squamous cell carcinoma, one of the following: * Aumolertinib + cisplatin or carboplatin with paclitaxel; * Aumolertinib + cisplatin or carboplatin with albumin-bound paclitaxel; or * Aumolertinib + cisplatin or carboplatin with gemcitabine Aumolertinib + platinum-based doublet chemotherapy Cisplatin For adenocarcinoma, either: * Aumolertinib + cisplatin with pemetrexed, or * Aumolertinib + carboplatin with pemetrexed For squamous cell carcinoma, one of the following: * Aumolertinib + cisplatin or carboplatin with paclitaxel; * Aumolertinib + cisplatin or carboplatin with albumin-bound paclitaxel; or * Aumolertinib + cisplatin or carboplatin with gemcitabine Aumolertinib + platinum-based doublet chemotherapy Gemcitabine For adenocarcinoma, either: * Aumolertinib + cisplatin with pemetrexed, or * Aumolertinib + carboplatin with pemetrexed For squamous cell carcinoma, one of the following: * Aumolertinib + cisplatin or carboplatin with paclitaxel; * Aumolertinib + cisplatin or carboplatin with albumin-bound paclitaxel; or * Aumolertinib + cisplatin or carboplatin with gemcitabine Aumolertinib + platinum-based doublet chemotherapy Carboplatin For adenocarcinoma, either: * Aumolertinib + cisplatin with pemetrexed, or * Aumolertinib + carboplatin with pemetrexed For squamous cell carcinoma, one of the following: * Aumolertinib + cisplatin or carboplatin with paclitaxel; * Aumolertinib + cisplatin or carboplatin with albumin-bound paclitaxel; or * Aumolertinib + cisplatin or carboplatin with gemcitabine Aumolertinib + platinum-based doublet chemotherapy Paclitaxel For adenocarcinoma, either: * Aumolertinib + cisplatin with pemetrexed, or * Aumolertinib + carboplatin with pemetrexed For squamous cell carcinoma, one of the following: * Aumolertinib + cisplatin or carboplatin with paclitaxel; * Aumolertinib + cisplatin or carboplatin with albumin-bound paclitaxel; or * Aumolertinib + cisplatin or carboplatin with gemcitabine Aumolertinib + platinum-based doublet chemotherapy Pemetrexed For adenocarcinoma, either: * Aumolertinib + cisplatin with pemetrexed, or * Aumolertinib + carboplatin with pemetrexed For squamous cell carcinoma, one of the following: * Aumolertinib + cisplatin or carboplatin with paclitaxel; * Aumolertinib + cisplatin or carboplatin with albumin-bound paclitaxel; or * Aumolertinib + cisplatin or carboplatin with gemcitabine
- Primary Outcome Measures
Name Time Method Progression Free Survival (PFS) as Assessed by Blinded Independent Central Review (BICR) Per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 Up to 5 years PFS is defined as the time from date of randomization until date of disease progression or death due to any cause, whichever occurs first.
- Secondary Outcome Measures
Name Time Method Disease Control Rate (DCR) as Assessed by BICR Per RECIST v1.1 Up to 5 years DCR is defined as the proportion of participants who have a best overall response of complete response or partial response or stable disease.
Overall Survival (OS) Up to 6 years OS is defined as the time from date of randomization until death from any cause.
Objective Response Rate (ORR) as Assessed by BICR Per RECIST v1.1 Up to 5 years ORR is defined as proportion of participants who achieve a complete response or partial response at any time before progressive disease or initiating a subsequent anticancer therapy.
Number of Participants With Electrocardiogram (ECG) Abnormalities From date of treatment initiation until discontinuation from treatment (plus 28 days for TEAEs), up to 5 years This outcome will evaluate incidence of participants with ECG abnormalities
PFS as Assessed by the Investigator Per RECIST v1.1 Up to 5 years PFS is defined as the time from date of randomization until date of disease progression or death due to any cause, whichever occurs first.
ORR as Assessed by the Investigator Per RECIST v1.1 Up to 5 years ORR is defined as the proportion of participants who achieve a complete response or partial response at any time before disease progression or initiating a subsequent anticancer therapy.
Tumor Growth Rate (TGR) as Assessed by BICR Per RECIST v1.1 Up to 5 years TGR is defined as the constant exponential growth rate estimated using the sum of longest diameters based on radiological tumor assessment per RECIST v1.1.
DCR as Assessed by the Investigator Per RECIST v1.1 Up to 5 years DCR is defined as the proportion of participants who have a best overall response of complete response or partial response or stable disease.
TGR as Assessed by the Investigator Per RECIST v1.1 Up to 5 years TGR is defined as the constant exponential growth rate estimated using the sum of longest diameters based on radiological tumor assessment per RECIST v1.1.
DOR as Assessed by the Investigator Per RECIST v1.1 Up to 5 years DOR is defined as date of first response (complete response or partial response) until the date of disease progression or death due to any cause, whichever occurs first.
DepOR as Assessed by the Investigator Per RECIST v1.1 Up to 5 years DepOR is defined as the relative change in target lesion tumor size (calculated as the sum of the longest diameters of the target lesions, in the absence of new lesions or progression of nontarget lesions) as compared to baseline.
Quality of Life as Assessed by the National Cancer Institute Patient Reported Outcomes Common Terminology Criteria for Adverse Events (NCI PRO-CTCAE) Questionnaire Up to 5 years NCI PRO-CTCAE questionnaire responses are scored from 0 to 4, wherein lower values represent a better outcome. For this trial, the burden of symptoms that will be captured by this questionnaire comprises nausea, diarrhea, and rash.
Rate of Circulating Tumor DNA (ctDNA) Clearance 6 weeks ctDNA clearance is defined as when a detectable EGFR mutation in ctDNA at baseline becomes undetectable or drops below a predetermined threshold. Rate of ctDNA clearance is defined as 100 × number of participants who are ctDNA-negative at 6 weeks divided by number of participants who are ctDNA-positive at baseline.
Plasma Concentration of Aumolertinib Up to approximately 5 months Plasma concentration is defined as the measured drug concentration of aumolertinib.
Plasma Concentration of Aumolertinib Metabolite Up to approximately 5 months Plasma concentration is defined as the measured drug concentration of aumolertinib metabolite.
Number of Participants With Treatment Emergent Adverse Events (TEAEs) From date of treatment initiation until discontinuation from treatment (plus 28 days for TEAEs), up to 5 years This outcome will evaluate the incidence of participants with TEAEs, graded according to NCI CTCAE V5.
Number of Participants With Laboratory Abnormalities From date of treatment initiation until discontinuation from treatment (plus 28 days for TEAEs), up to 5 years This outcome will evaluate incidence of participants with laboratory abnormalities, graded according to NCI CTCAE V5.
Duration of Response (DOR) as Assessed by BICR Per RECIST v1.1 Up to 5 years DOR is defined as date of first response (complete response or partial response) until date of disease progression or death due to any cause, whichever occurs first
Depth of Response (DepOR) as Assessed by BICR Per RECIST v1.1 Up to 5 years DepOR is defined as the relative change in target lesion tumor size (calculated as the sum of the longest diameters of the target lesions, in the absence of new lesions or progression of nontarget lesions) as compared to baseline.
Number of Participants With Serious Adverse Events (SAEs) From date of treatment initiation until discontinuation from treatment (plus 28 days for TEAEs), up to 5 years This outcome will evaluate incidence of participants with SAEs, be graded according to NCI CTCAE V5.
Trial Locations
- Locations (7)
Northwest Medical Specialties, PLLC
🇺🇸Tacoma, Washington, United States
QCCA - Mission Blood & Cancer
🇺🇸Des Moines, Iowa, United States
Memorial Cancer Institute
🇺🇸Pembroke Pines, Florida, United States
SCRI - Tennessee Oncology PLLC- Chattanooga
🇺🇸Chattanooga, Tennessee, United States
Highlands Oncology Group
🇺🇸Springdale, Arkansas, United States
SCRI - Tennessee Oncology- Nashville
🇺🇸Nashville, Tennessee, United States
Summit Health
🇺🇸Florham Park, New Jersey, United States